在接受积极治疗的晚期癌症患者中非计划性再入院:多中心,回顾性研究
Sun Young Lee1, Hong Jun Kim2, Shin Hye Yoo3
1Public Healthcare Center, Seoul National University Hospital, Seoul, Korea.
Cancer research and treatment
|January 8, 2026
概括
意外的癌症再入院通常是由于疾病进展,导致更长的住院时间和更高的死亡率. 家庭出院增加了进一步入院的风险,突出了对晚期癌症患者更好的出院后护理的需要.
科学领域:
- 在瘤学瘤学.
- 医疗保健管理的管理
- 患者的治疗结果.
背景情况:
- 在接受活性治疗的晚期癌症患者中,未计划的再入院研究不足.
- 这些再接收增加了医疗保健成本,并扰乱了患者的护理.
- 有限的数据存在于这个人群的具体原因和结果.
研究的目的:
- 调查晚期癌症患者意外再入院的原因,临床特征和结果.
- 确定与出院后早期非计划性住院使用相关的因素.
主要方法:
- 在韩国 (2019年) 542名患有晚期固体瘤的患者进行了回顾性多中心研究.
- 在先前住院1个月内重新入院被分类为:癌症进展,与治疗有关的或其他.
- 对幸存者在出院后1个月内计划外入院的分析.
主要成果:
- 癌症进展 (42.6%) 是再入院的主要原因,与更长的住院时间 (中位数为12天) 和更高的死亡率 (23.4%) 相关.
- 与治疗相关的再入院 (37.3%) 停留时间较短 (8天),死亡率较低 (8.4%).
- 在幸存者中,24.9%的人在1个月内经历了额外的非计划性医院访问;在家出院是显著的预测因素 (再入院的aOR为4.82).
结论:
- 癌症进展是无计划再入院的主要驱动因素,与更糟糕的结果相关.
- 家庭出院是随后意外住院的关键风险因素,需要加强出院后的监测.
- 改善护理协调和监测对于减少再入院和改善晚期癌症患者的治疗结果至关重要.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
637
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
